Elrig

MARCH 25, 2025

It will also cover recent advancements in broadening their application, including innovative approaches to ensure their safety and efficacy, the use of targeted delivery to reach disease-relevant tissues as well as success stories in bringing therapeutic oligonucleotides to the clinic.

RNA

The Open Targets Blog

JANUARY 30, 2025

  “Sam has an exceptional talent in software engineering, and his contributions reflect a deep understanding of both the technical and biological aspects required for bioinformatics tool development,” says Laura Luebbert, now a postdoctoral fellow in the Sabeti lab at the Broad Institute of MIT and Harvard and Harvard University.

Bioinformatics

Broad Institute

JULY 9, 2025

He leverages multimodal data to develop translational approaches for precision medicine in diabetes and metabolic disease, including polygenic risk scores and therapeutic target identification. His expertise spans bioinformatics through to clinical translation, including multi-omics, machine learning, and perturbation data.

Bioinformatics

Codon

JULY 21, 2025

There are signs that what we currently call “rheumatoid arthritis” may turn out to be more than one disease. Tools like genetic sequencing made it possible to diagnose cancer based on mutations, rather than location, and made targeting of genetic diseases possible.

Science

Drug Target Review

DECEMBER 13, 2023

Combinatorial analytics approaches identify combinations of features that together are associated with the disease phenotype in patient sub-groups, capturing the non-linear effects of interactions between multiple genes. The combinatorial approach is considerably more sensitive than GWAS and requires much smaller patient populations.

Bioinformatics

Drug Target Review

AUGUST 11, 2023

1 The study reveals a novel bioinformatic approach and tool that holds the potential to empower researchers in designing vaccines capable of inducing a stronger immune response. By selecting specific segments of proteins that elicit robust immune reactions, these vaccines could offer enhanced protection against diseases.

Vaccine

Chemical Biology and Drug Design

JANUARY 1, 2024

Chinese motherwort (YiMuCao, Leonurus japonicus ) is a traditional Chinese herb showing beneficial effects for obstetrical and gynecological diseases. Then, Bioinformatics was applied to sort out the candidate interacting with Stachydrine as well as its expression and downstream target in BC.

Bioinformatics

The Open Targets Blog

OCTOBER 31, 2023

Data integration under common ontological terms will aid in categorising diseases, genes, and agents. Open Targets delivers easy-to-navigate aggregated information and evidence linking therapies, genes, and diseases.  The Open Targets Platform had several advantages as a backbone infrastructure for this purpose. earlier this year.

Bioinformatics

Drug Target Review

JULY 12, 2023

These assays provide insights into the molecular mechanisms of disease biology and drug response, enabling the characterisation of gene expression profiles and deviations in diseased cells. Importantly, transcriptomics information shows that certain aspects of a disease change the gene expression profile.

Biochemical Assays

Chemical Biology and Drug Design

FEBRUARY 7, 2024

Hydroxysafflor yellow A (HSYA), the main active component in the medical and edible dual-purpose plant safflower, has previously shown anti-inflammatory effects in various diseases. However, the specific impact of HSYA on OA remains unclear. Western blot was employed to investigate NF-κB transcription factors in chondrocyte metabolism.

Bioinformatics

Drug Target Review

MARCH 19, 2024

In other words, a disease state may cause a change in vitamin A levels rather than the vitamin A levels causing a change in disease state. Again, in this circumstance adding the vitamin will not help therapeutically with the disease state. Secondly, it’s difficult to separate causation from reverse causation.

Laboratories

The Open Targets Blog

OCTOBER 24, 2023

Amir Feizi is the Director of Bioinformatics at OMass Therapeutics, a spinout from Professor Dame Carol Robinson’s Laboratory at the University of Oxford. OMass Therapeutics is using a new technology platform to develop treatments for rare immunological and genetic diseases with high unmet patient needs.

Bioinformatics

Broad Institute

JULY 10, 2023

Credit: Allison Colorado, Broad Communications Arriving in the Bay Area after a childhood in increasingly diverse surroundings, Martin became acutely aware of health disparities and the profound differences in disease prevalence among different populations. I wanted to know how I could have any impact on studying genetic diversity.”

Disease

Broad Institute

SEPTEMBER 30, 2024

Today, about a third of Broad’s Terra users are from the public health workforce; in the US, 76 state and local public health labs use the platform for preventing and monitoring infectious disease spread in their communities. This was true in the US and all the more in the Global South, where the burden of infectious disease is the highest.

Bioinformatics

The Open Targets Blog

AUGUST 13, 2024

It’s a fascinating study in collaboration, negotiation, influence and decision making as we aim to understand where we can build collaborative projects that will have impact in our ability to understand and treat disease –  projects such as Open-IBD. We are often treating the symptoms rather than the causes of disease.

Bioinformatics

The Open Targets Blog

FEBRUARY 29, 2024

  With a background in biochemistry and bioinformatics, Lucy was interested in exploring how bioinformatics was applied to real-world healthcare data. I just graduated with a degree in Bioinformatics, and I was interested to see how the skills I learned could be applied.

International

Elrig

APRIL 29, 2024

With a background in Bioinformatics and Computational Biology, she has a keen interest in using technology to solve problems in healthcare and medicine. Bioinformatics is all about bringing together different areas of knowledge.

Bioinformatics

Broad Institute

AUGUST 20, 2024

She’d always been interested in disease — why people got sick, why some illnesses could send you to a hospital while others could be treated at home. As she grew older, however, she realized she was more interested in learning about the roots of disease and the genes that caused them. Any errors are part of the code itself.

Science

The Pharma Data

NOVEMBER 25, 2020

Egle has leveraged its unique bioinformatic and translational capabilities to successfully identify targets that will now be pursued under the terms of the alliance. Upon achievement of the target identification, Egle will receive an R&D milestone payment and investment from Takeda.

Research

Broad Institute

AUGUST 29, 2016

Software engineering at Broad is about building creative solutions to catalog, manage, and analyze that dizzying volume of data, and make it available so that researchers around the world can do research that matters: understanding the genome and curing disease.

Bioinformatics

The Pharma Data

MARCH 2, 2021

Senior Vice President and Global Head of Cardiometabolic Diseases Research, Boehringer Ingelheim. Obesity is a complex chronic disease that requires long-term management. It is among the leading risk factors for several cardio-metabolic diseases, such as heart disease, ischemic stroke, liver diseases incl.

Treatment

Vial

DECEMBER 5, 2023

Among others, NGS has led to the identification of disease-causing variants and novel drug targets and an improved understanding of complex biological events, e.g., the heterogeneity of tumors. 2022) recommend matching interventions to specific patient characteristics should be implemented early in the disease course. Fountzilas et al.

Clinical Trials

DrugBank

FEBRUARY 12, 2025

In Silico Drug Repurposing Advances in bioinformatics and systems biology have fueled the rise of repurposing of in silico drugs. CMap utilizes gene expression profiles to connect drugs, genes, and diseases, enabling researchers to identify potential repurposing candidates based on their transcriptional signatures.

Cell Based Assays

The Open Targets Blog

AUGUST 7, 2023

Following my interest in natural sciences, I moved to Novosibirsk (central Siberia) as soon as I was able, to study general biology, with a focus on statistical genetics and bioinformatics. I am an academic scientist through and through: I’ve been working in academia since university. What is on your to-do list in this new role?

Bioinformatics

The Pharma Data

JANUARY 24, 2021

Professor of Medicine, Section of Infectious Diseases and Global Health and director of the Duchossois Family Institute at the University of Chicago, has joined its scientific advisory board. His research focuses on the role of the microbiome in immune defense and disease resistance. “We Diversigen, Inc.

Research

Broad Institute

AUGUST 4, 2022

By Tracy Hampton August 4, 2022 Credit: National Institutes of Allergy and Infectious Diseases, National Institutes of Health Colorized scanning electron micrograph of a B cell lymphocyte from a human donor.

Bioinformatics

The Pharma Data

DECEMBER 27, 2020

28, 2020 /PRNewswire/ — United Therapeutics Corporation (Nasdaq: UTHR) announced today an agreement to acquire a Rare Pediatric Disease Priority Review Voucher (PRV), which it plans to use with a forthcoming New Drug Application (NDA) with the U.S. SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Food and Drug Administration (FDA).

FDA

The Open Targets Blog

APRIL 19, 2022

The Open Targets Platform integrates data from several sources, making connections between targets and diseases or phenotypes and providing context for these associations. Do the most relevant suggested connections between targets and diseases represent evidence? In the context of this post, we will focus on the first question.

Disease

The Pharma Data

DECEMBER 16, 2020

This includes Evotec’s data analysis platform “PanHunter”, a proprietary, integrated, user-centred bioinformatics platform which facilitates the analysis of PanOmics data integrated with other metadata sets.

Targeted Protein Degradation

LifeSciVC

AUGUST 30, 2022

To counter this, our head of bioinformatics Mike Seiler started “Data Friday” – sharing your latest data at the end of the week on slack – it could be anything – unpolished data, raw data, an interesting observation, negative data for trouble shooting, anything could be shared.

Science

The Pharma Data

JULY 27, 2021

The acquisition includes Teneobio’s proprietary bispecific and multispecific antibody technologies, which will enable significant acceleration and efficiency in the discovery and development of new molecules that have the potential to treat a wide range of important diseases across Amgen’s core therapeutic areas. Reese, M.D.,

Production

The Pharma Data

SEPTEMBER 11, 2021

We look forward to working with Twist on molecular targets in a broad range of disease areas,” added Wood. Wood, Ph.D., Senior Corporate Vice President and Global Head of Discovery Research at Boehringer Ingelheim. “We About Twist Bioscience Corporation.

DNA

The Pharma Data

OCTOBER 27, 2020

Tyvaso in pulmonary hypertension due to interstitial lung disease (PH-ILD). Tyvaso also showed benefits across several key subgroups, including etiology of PH-ILD, disease severity, age, gender, baseline hemodynamics, and dose. Tyvaso in patients with chronic fibrosing interstitial lung disease (CFILD) — TETON.

FDA

The Pharma Data

NOVEMBER 15, 2020

” “We are committed to advancing innovative science and transformative medicines for people affected by different immune mediated diseases”, says James Sabry , Global Head, Roche Pharma Partnering. ” About Immune Mediated Diseases. A wide range of human diseases is driven by deregulated immune function.

Small Molecule

The Premier Consulting Blog

JUNE 18, 2023

One exciting application of these technologies is the use of in silico trials in the development of novel therapies for rare diseases. However, with rare diseases there may be no available treatments that could serve as SoC or active control in a clinical trial and assigning patients to placebo may be unethical.

Drug Development

DrugBaron

NOVEMBER 22, 2022

In 2015, Methuselah Health was founded to investigate the role of proteome instability during ageing, and the extent to which the instability of specific proteins might underlie development of age-related diseases – a concept that arose from the ground-breaking work of Professor Miro Radman (which DrugBaron highlighted previously).

Bioinformatics

Broad Institute

APRIL 25, 2024

He started to imagine how the deadly and contagious disease, if confirmed, might spread to half the city’s population. Eight of the 20 patients died, but the spread of the disease in Nigeria stopped there. Blood and urine samples from the man were waiting for Happi in his lab. Happi felt chilled. They called the idea Sentinel.

Virus